Related Experiment Video
Updated: Mar 31, 2026
Murine Ileocolic Bowel Resection with Primary Anastomosis
Published on: October 29, 2014
Development and External Validation of a Predictive Model for Postoperative Recurrence of Crohn's Disease in the
Matthieu Allez1, Michiel T J Bak2, Sofia Brand3
1Research Institute, McGill University Health Centre (MUHC), Montreal, Quebec, Canada; Department of Gastroenterology, Hôpital Saint-Louis, APHP, Paris, France; INSERM U1342, Institut de Recherche Saint-Louis, Université Paris Cité, Paris, France.
Background & Aims:
Ileocolonic resection remains common in Crohn's disease (CD) despite increasing biologic use. The aim of this study was to identify risk factors for postoperative recurrence and to assess prophylactic biologic therapy effectiveness in relation to risk factors.
Methods:
This prospective multicentre study included adults with CD undergoing ileocolonic resection (ICR). The primary endpoint was endoscopic recurrence (modified Rutgeerts score ≥i2b) within the year following surgery. Factors associated with endoscopic recurrence were identified using a logistic regression model. A composite time-to-event endpoint was defined for long-term follow-up based on clinical, endoscopic, and/or imaging data. An external validation of our predictive model was performed in 2 independent international cohorts.
Results:
Among 632 patients (median disease duration, 7.8 years), 78% had prior biologic exposure; 44% received postoperative biologic prophylaxis. Endoscopic recurrence occurred in 237 patients (37.5%). In multivariable model, risk factors included: male sex (odds ratio [OR], 1.97; 95% confidence interval [CI], 1.38-2.83), active smoking (OR, 2.37; 95% CI, 1.56-3.62), previous ICR (OR, 1.78; 95% CI, 1.13-2.82), previous exposure to 1 (OR, 2.15; 95% CI, 1.37-3.42) or more than 1 biologic (OR, 2.41; 95% CI, 1.39-4.22). Biologic prophylaxis significantly reduced recurrence risk (OR, 0.31; 95% CI, 0.20-0.45), independently of these risk factors. A predictive nomogram based on multivariable analysis achieved an area under the receiver operating characteristic curve of 0.72, with similar performance in external cohorts. Clinically significant recurrence, observed in 22.9%, 36.5%, and 53.2% at 3, 5, and 10 years, was associated with severity of early endoscopic recurrence.
Conclusions:
Postoperative recurrence risk can be estimated using a model based on clinical factors. Biologic prophylaxis is highly effective in preventing early endoscopic recurrence, regardless of risk profile.
Clinicaltrials:
gov, Number: NCT03458195.
More Related Videos
07:13Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
Published on: April 18, 2025
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
01:21Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids